Publications by authors named "Ramon Benz"
Article Synopsis
- Somatostatin receptor type 2 (SSTR2) is commonly found on certain tumors, including gastro-entero-pancreatic neuroendocrine tumors and breast cancer, making it a target for therapy.
- Researchers developed a novel fluorescent-peptide antagonist, Octo-Fluo, that works with genetically engineered CAR T-cells to selectively trigger cell death in SSTR2-expressing cancer cells.
- In laboratory and animal studies, Octo-Fluo enhanced the effectiveness of AdFITC(E2)-CAR T-cells against tumors, but high concentrations of Octo-Fluo could reduce its effectiveness by saturating both the CAR and SSTR2, highlighting the importance of dosage for treatment success.
Antibody-based therapeutics represent an important class of biopharmaceuticals in cancer immunotherapy. CD3 bispecific T-cell engagers activate cytotoxic T-cells and have shown remarkable clinical outcomes against several hematological malignancies. The absence of a costimulatory signal through CD28 typically leads to insufficient T-cell activation and early exhaustion.
View Article and Find Full Text PDF